Facebook Billionaire Investing in a Shocking New Industry
Peter Thiel, the billionaire investor behind Facebook, PayPal, and eBay, has a new darling industry in his sights. And he's betting a massive $210 million on its success. That's not pocket change.
And today, you could get in on the ground floor

OXB Insider Trading (Oxford Biomedica)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £917,626.72
Insider Selling (Last 12 Months): £143,959.64

Oxford Biomedica Insider Trading History Chart

Oxford Biomedica Share Price & Price History

GBX 1,292
+0.30 (1.20%)
As of 06/18/2021 10:00 PM ET
Days: 30 | 90 | 365
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1Interstate Cannabis

Oxford Biomedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2020Andrew HeathInsiderSell15,756GBX 869£136,919.64
10/22/2020Martin DiggleInsiderBuy25,000GBX 780£195,000
6/30/2020Andrew HeathInsiderSell1,000GBX 704£7,040
6/22/2020Martin DiggleInsiderBuy89,434GBX 808£722,626.72
5/27/2020Lorenzo TallarigoInsiderBuy365GBX 733£2,675.45
5/6/2020Stuart PaynterInsiderBuy1,472GBX 675£9,936
4/24/2020Lorenzo TallarigoInsiderBuy367GBX 729£2,675.43
3/25/2020Lorenzo TallarigoInsiderBuy482GBX 555£2,675.10
2/26/2020Lorenzo TallarigoInsiderBuy438GBX 610£2,671.80
1/31/2020Lorenzo TallarigoInsiderBuy445GBX 601£2,674.45
12/19/2019Lorenzo TallarigoInsiderBuy415GBX 644£2,672.60
11/26/2019Lorenzo TallarigoInsiderBuy470GBX 569£2,674.30
9/25/2019Lorenzo TallarigoInsiderBuy482GBX 554£2,670.28
9/12/2019Martin DiggleInsiderBuy17,953GBX 577£103,588.81
8/23/2019Lorenzo TallarigoInsiderBuy427GBX 626£2,673.02
7/25/2019Lorenzo TallarigoInsiderBuy368GBX 730£2,686.40
6/26/2019Lorenzo TallarigoInsiderBuy370GBX 722£2,671.40
5/23/2019Lorenzo TallarigoInsiderBuy388GBX 689£2,673.32
4/25/2019Lorenzo TallarigoInsiderBuy379GBX 706£2,675.74
4/23/2019Andrew HeathInsiderBuy3,312GBX 673£22,289.76
3/25/2019Lorenzo TallarigoInsiderBuy382GBX 695£2,654.90
2/25/2019Lorenzo TallarigoInsiderBuy413GBX 644£2,659.72
2/6/2019Andrew HeathInsiderSell2,832GBX 703£19,908.96
2/4/2019Andrew HeathInsiderBuy2,000GBX 709£14,180
1/24/2019Lorenzo TallarigoInsiderBuy383GBX 694£2,658.02
1/18/2019Stuart PaynterInsiderBuy1,622GBX 613£9,942.86
11/23/2018Lorenzo TallarigoInsiderBuy406GBX 654£2,655.24
10/22/2018Lorenzo TallarigoInsiderBuy353GBX 754£2,661.62
9/24/2018Lorenzo TallarigoInsiderBuy291GBX 913£2,656.83
8/22/2018Lorenzo TallarigoInsiderBuy302GBX 881£2,660.62
8/7/2018John DawsonInsiderSell10,046GBX 890£89,409.40
7/23/2018Lorenzo TallarigoInsiderBuy306GBX 867£2,653.02
6/22/2018Lorenzo TallarigoInsiderBuy262GBX 1,019£2,669.78
See Full Table
Oxford Biomedica logo
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More on Oxford Biomedica

Today's Range

Now: GBX 1,292

50 Day Range

MA: GBX 1,108.56

52 Week Range

Now: GBX 1,292


110,915 shs

Average Volume

163,266 shs

Market Capitalization

£1.07 billion

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Oxford Biomedica?

Oxford Biomedica's top insider investors include:
  1. Andrew Heath (Insider)
  2. Lorenzo Tallarigo (Insider)
  3. Martin Diggle (Insider)
  4. Stuart Paynter (Insider)
Facebook Billionaire Investing in a Shocking New Industry
Peter Thiel, the billionaire investor behind Facebook, PayPal, and eBay, has a new darling industry in his sights. And he's betting a massive $210 million on its success. That's not pocket change.
And today, you could get in on the ground floor